Our Blog
Sermes CRO: AEMPS approves the NC1 advance therapy drug for patients with chronic traumatic medullary injury
The NC1 cell therapy drug for patients with chronic traumatic spinal cord injury has been authorized by the AEMPS for public use at hospital use. NC1 has been developed by Dr. Vaquero and Dr. Zurita at Puerta de Hierro University Hospital with the collaboration in the clinical research of Sermes CRO and the Sermes Foundation.
The NC1 cell therapy drug for patients with chronic traumatic spinal cord injury has been authorized by the AEMPS for public use at hospital use. NC1 has been developed by Dr. Vaquero and Dr. Zurita at Puerta de Hierro University Hospital with the collaboration in the clinical research of Sermes CRO and the Sermes Foundation.
Science has come a little further and now patients with spinal cord injury have a new therapy that has a positive impact on their quality of life. Sermons has collaborated in clinical research to achieve this milestone.
Both at Sermes CRO and Sermes Foundation, are very proud to have collaborated so that this project has seen the light. We want to take the opportunity to congratulate all our team that has participated in the development of this revolutionary new therapy over several years, and that has been involved both professionally and emotionally in an exemplary way.
For more information about the NC1 please click here
